Pandorum Technologies Raises $18M Series B to Advance Programmable…

Team S · 2026-02-09T14:05:57.000Z

Biotech startup Pandorum Technologies has successfully closed a $18 million Series B funding round led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family, among others. This fresh capital will support the advancement of Pandorum’s clinical-stage regenerative medicine programs, scale up manufacturing capabilities, and expand global operations across the U.S., Japan, and the Middle East. Founded by Tuhin Bhowmick and Arun Chandru, Pandorum specializes in programmable, exosome-based therapies designed to treat a broad range of conditions starting with ocular surface diseases such as corneal dystrophies. Its lead program Kuragenx has already received U.S. FDA Orphan Drug Designation for Neurotrophic Keratitis, and the company is scaling clinical development and regulatory infrastructure to bring its tissue-regenerative platform into wider therapeutic areas, including liver, lung, and inflammatory disorders. Pandorum operates with a globally distributed strategy, partnering with AGC Biologics for manufacturing in the U.S. and Europe and Nucelion Therapeutics (a Bharat Biotech subsidiary) across the Asia-Pacific region, while pursuing strategic access expansions in other key markets. This Series B will also strengthen Pandorum’s regulatory capabilities and help accelerate broader trial efforts across multiple geographies.

Member Login Get Access

Pandorum Technologies Raises $18M Series B to Advance Programmable… | Newnex